Verteporfin

Bezeichnung:Verteporfin

CAS-Nr129497-78-5

Englisch Name:Verteporfin

CBNumberCB6505794

Summenformel2C41H42N4O8

Molgewicht1437.61

MOL-Datei129497-78-5.mol

Verteporfin physikalisch-chemischer Eigenschaften

storage temp.	-20°C
Löslichkeit	DMSO: soluble2mg/mL, clear (warmed)
Aggregatzustand	powder
Farbe	Black
Stabilität	Stable for 2 years from date of purchsae as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey	YHNBVDZVUQFVLS-RDSGBMLISA-N

Sicherheit

WGK Germany	3
HS Code	2933997500

Gefahreninformationscode (GHS)

Verteporfin Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Verteporfin was introduced in Switzerland as a second-generation photosensitizer for photodynamic therapy of wet age-related macular degeneration in patients with subfoveal choroidal neovascularisation. It is constituted of a mixture of two regioisomers resulting from nonselective monohydrolysis of the methyl tetraester. Upon irradiation with a lowenergy nonheat-generating laser light of 689nm wavelength, both regioisomeric benzoporphyrins are responsible for the local generation of singlet oxygen leading to free radical damage of neovascular endothelial cells in subfoveal lesions of patients with agerelated macular degeneration. The lipophilic drug is injected i.v. as a liposomal formulation in order to favor its uptake by plasma lipoproteins and distribution to cells with a high expression of low density lipoprotein receptors such as tumor and neovascular endothelial cells. Verteporfin is also being developed for the treatment of other eye diseases, nonmelanoma skin cancer and psoriasis.
Beschreibung
Verteporfin is a photosensitizer used during photodynamic therapy to eliminate abnormal blood vessels in the eye that are associated with conditions such as macular degeneration. It accumulates in these abnormal blood vessels and, when activated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces a highly reactive short-lived singlet oxygen and other reactive oxygen radicals, generating local damage to the endothelium and vessel occlusion. Verteporfin can also inhibit autophagosome formation by directly targeting and modifying p62, a scaffold and adaptor protein that binds both polyubiquitinated proteins destined for degradation and LC3 on autophagosomal membranes.
Originator
QLT Inc. (Canada)
Verwenden
Treatment of age-related macular degeneration
Verwenden
Verteporfin is a photosensitizer that is used in photodynamic therapy (PDT). Verteporfin can accumulate in tumor tissues allowing for 30 to 150 minutes optimal PDT after intravenous administration.
Trademarks
Visudyne (QLT).
Biochem/physiol Actions
Verteporfin is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as macular degeneration. Verteporfin accumulates in abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. Verteporfin localizes predominantly in mitochondria.
Lager
Store at -20°C
Einzelnachweise
References/Citations:

Verteporfin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

129497-78-5, Verteporfin Verwandte Suche:

Send Inquriy